140 related articles for article (PubMed ID: 36424904)
21. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.
Herweijer E; Feldman AL; Ploner A; Arnheim-Dahlström L; Uhnoo I; Netterlid E; Dillner J; Sparén P; Sundström K
PLoS One; 2015; 10(7):e0134185. PubMed ID: 26218492
[TBL] [Abstract][Full Text] [Related]
22. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
23. The Consensus Project: Participation in cervical cancer screening by the first cohorts of girls offered HPV vaccination at age 15-16 years in Italy.
Visioli CB; Giorgi Rossi P; Armaroli P; Iossa A; Rizzolo R; Bonelli LA; Venturino E; Carozzi FM; Bisanzi S; De Marco L; Giordano L; Camussi E; Del Mistro A; Zappa M
J Med Screen; 2023 Sep; 30(3):142-149. PubMed ID: 36999190
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.
Kurosawa M; Sekine M; Yamaguchi M; Kudo R; Hanley SJB; Hara M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Apr; 113(4):1435-1440. PubMed ID: 35100477
[TBL] [Abstract][Full Text] [Related]
25. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
26. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
[TBL] [Abstract][Full Text] [Related]
28. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
Verdoodt F; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
[TBL] [Abstract][Full Text] [Related]
29. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
[TBL] [Abstract][Full Text] [Related]
30. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
[TBL] [Abstract][Full Text] [Related]
31. Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study.
Kreusch T; Wang J; Sparén P; Sundström K
BMJ Open; 2018 Oct; 8(10):e024477. PubMed ID: 30282687
[TBL] [Abstract][Full Text] [Related]
32. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
34. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes.
Kharbanda EO; Vazquez-Benitez G; DeSilva MB; Naleway AL; Klein NP; Hechter RC; Glanz JM; Donahue JG; Jackson LA; Sheth SS; Greenberg V; Panagiotakopoulos L; Mba-Jonas A; Lipkind HS
JAMA Netw Open; 2021 Apr; 4(4):e214340. PubMed ID: 33818618
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
Dehlendorff C; Baandrup L; Kjaer SK
J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
[TBL] [Abstract][Full Text] [Related]
36. Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study.
Dick A; Rosenbloom JI; Gutman-Ido E; Lessans N; Cahen-Peretz A; Chill HH
BMC Pregnancy Childbirth; 2022 Feb; 22(1):166. PubMed ID: 35227233
[TBL] [Abstract][Full Text] [Related]
37. Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology.
Dorton BJ; Vitonis AF; Feldman S
Hum Vaccin Immunother; 2016 Jun; 12(6):1639-45. PubMed ID: 26839185
[TBL] [Abstract][Full Text] [Related]
38. Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia.
Yuill S; Egger S; Smith M; Velentzis L; Wrede CD; Bateson D; Canfell K
J Infect Dis; 2020 Jul; 222(3):499-508. PubMed ID: 32386228
[TBL] [Abstract][Full Text] [Related]
39. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
[TBL] [Abstract][Full Text] [Related]
40. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
